Navigation Links
Paragon BioTeck, Inc. Announces FDA Approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%

Tigard, OR (PRWEB) March 22, 2013

Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%, to dilate the pupil.

“This approval represents an important milestone not only for Paragon, but also within the eye care community as a whole,” said Patrick Witham, President and CEO of Paragon BioTeck. “Phenylephrine Hydrochloride Ophthalmic Solution has been marketed without FDA approval for decades, and during that time has been administered to millions of patients. With the increase in drug manufacturers domestically and abroad, FDA oversight over drug products is more important than ever. The FDA approval process is in place to ensure both that a drug is safe and that it’s manufactured under appropriate controls and oversight.”

About Phenylephrine Hydrochloride Ophthalmic Solution
Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is an alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly a-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial muscle of the iris.

Phenylephrine Hydrochloride Ophthalmic Solution Important Safety Information
Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis, as well as in pediatric patients under the age of one due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. It’s for topical ophthalmic use only, and not for injection.

Serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, some fatal, and significant elevations in blood pressure have been reported. Caution is advised in pediatric patients less than five years of age, and in patients with elevated blood pressure, cardiovascular disease or hyperthyroidism. Blood pressure should be monitored in patients with cardiovascular or endocrine disease. Rebound miosis has been reported one day after instillation.

Ocular adverse reactions include eye pain and stinging on instillation, temporary blurred vision and photophobia. Cardiovascular adverse reactions include increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage.

About Paragon BioTeck, Inc.
Paragon BioTeck is a privately held ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight. For more information on the company and its work, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Price Match Guarantee for Comparable Medical Weight Loss Plans
2. Number One Provider of Hearing Aids in Medford OR, Imaginears, Announces Launch of New Website
3. Sharon Kleyne Announces Investment into Fresh Water IP Technology
4. Manatee Works Announces Second Generation Mobile Decoding Engine
5. Depression Treatment Announces 2013 Blog Award Winners
6. Cornell Dubilier Announces Long-Life Ultracapacitors
7. MyoNatural Announces New Offer for Chiropractors and Doctors Offices Around the US
8. MinuteHound Announces Time and Attendance Solutions for Fitness Centers and Chains
9. La Jolla Vein Care Announces that Nisha Bunke-Paquette, M.D., FACPh, Inducted As a Fellow Of The American College Of Phlebology
10. NLN Foundation for Nursing Education Announces 2013 Nursing Education Scholarship Program Promoting Academic Progression
11. Dennis R. Hill MD Announces Launch of High Dose Rate Brachytherapy of Prostate Cancer Website
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
(Date:9/9/2017)... ... ... – Monday, September 18 th .The Brain Tumor Foundation (BTF) begins a ... public.Where:  BTF,s Mobile MRI Unit – a 70 ... D.C.What:BTF brings its nationwide initiative, the Road to Early Detection Sponsor-A-City Campaign ...
Breaking Medicine Technology: